Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Our speaker meetings help healthcare professionals stay up-to-date with the latest scientific knowledge and advancements in clinical practice across all clinical applications. If you would like to receive more information, please contact your local sales representative.

Upcoming Meetings
Past Meetings

Dec 3, 2026

Belgrade 2026: Therakos Expert Meeting on ECP in GVHD and CTCL

Belgrade, Serbia

Dec 3 - 4, 2026

Operator Day DACH

Berlin, Germany

Nov 23, 2026

CTCL in Clinical Practice: From Early Recognition to Modern Treatment

Vicenza, Italy

Nov 19 - 20, 2026

ECP Operator Day for NHSBT

Windsor, UK

Nov 13, 2026

CTCL in Clinical Practice: From Early Recognition to Modern Treatment

Reggio Calabria, Italy

Oct 29, 2026

Pan-London GvHD Meeting 2026

London, UK

Oct 29 - 30, 2026

Nordic Operators Day 2026

Stockholm, Sweden

Filter by:

Oct 16, 2026

Extracorporeal photopheresis: Who and when – understanding the role of ECP in different GvHD phenotypes

Lisbon, Portugal

Oct 8, 2026

THERAKOS™ CELLEX™ Photopheresis System Workshop

Paris, France

Oct 6, 2026

Current and emerging treatment approaches in GvHD

Stockholm, Sweden

Sep 29 - 30, 2026

5th Advancing Immunomodulation Meeting

London, UK

Sep 17, 2026

Operators Day UK

Birmingham, UK

Jul 3, 2026

The status quo in managing GvHD with ECP

Essen, Germany

Jun 25 - 26, 2026

Operator Day

Paris, France

Jun 18 - 19, 2026

6th Workshop on Solid Organ Transplantation - Potential roles of ECP in SOT

Monte Carlo, Monaco

Jun 16, 2026

Current and emerging treatment approaches for acute and chronic GvHD

Rigshospitalet, Denmark

Jun 11, 2026

ECP in heart transplantation: Potential mechanisms of action, efficacy and clinical practice

Padova, Italy

Jun 4, 2026

Treating CTCL patients in 2026

Nancy, France

May 8, 2026

CTCL and GvHD Skin Manifestations – Current Perspectives in Diagnosis and Therapy

Vienna, Austria

Apr 17, 2026

ECP in GvHD: Evidence in clinical practice

Bari, Italy

Feb 27, 2026

Tailoring extracorporeal photopheresis for low body weight patients’ needs

Porto, Portugal

Nov 27, 2025

Therapeutic Synergy in GvHD: A Clinical Perspective

Leicester, United Kingdom

Nov 26, 2025

Therapeutic Synergy in GvHD: A Clinical Perspective

Sheffield, United Kingdom

Nov 6 - 7, 2025

Operator Days Rotherham

Rotherham, UK

Oct 27, 2025

Treating Sézary Syndrome patients in 2025

St Etienne Hospital, France

Sep 17 - 19, 2025

Operator Days Dublin. This event is in French

Dublin, Ireland

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Belgrade 2026: Therakos Expert Meeting on ECP in GVHD and CTCL

Operator Day DACH

CTCL in Clinical Practice: From Early Recognition to Modern Treatment

ECP Operator Day for NHSBT

CTCL in Clinical Practice: From Early Recognition to Modern Treatment

Pan-London GvHD Meeting 2026

Nordic Operators Day 2026

Extracorporeal photopheresis: Who and when – understanding the role of ECP in different GvHD phenotypes

THERAKOS™ CELLEX™ Photopheresis System Workshop

Current and emerging treatment approaches in GvHD

5th Advancing Immunomodulation Meeting

Operators Day UK

The status quo in managing GvHD with ECP

Operator Day

6th Workshop on Solid Organ Transplantation - Potential roles of ECP in SOT

Current and emerging treatment approaches for acute and chronic GvHD

ECP in heart transplantation: Potential mechanisms of action, efficacy and clinical practice

Treating CTCL patients in 2026

CTCL and GvHD Skin Manifestations – Current Perspectives in Diagnosis and Therapy

ECP in GvHD: Evidence in clinical practice

Tailoring extracorporeal photopheresis for low body weight patients’ needs

Therapeutic Synergy in GvHD: A Clinical Perspective

Therapeutic Synergy in GvHD: A Clinical Perspective

Operator Days Rotherham

Treating Sézary Syndrome patients in 2025

Operator Days Dublin. This event is in French

Discover more

Courses

Webinars

Symposia

Ask the Expert

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS